Previous 10 | Next 10 |
- Results suggest that developing stimulant formulations with abuse deterrent properties by non-oral routes may potentially reduce negative consequences of misuse, abuse, and diversion of stimulant medication - Company’s l ead investigational program...
- L ead program, ADAIR , advancing toward completion of patient enrollment and treatment in ongoing SEAL study - Selection of final formulation completed for second development program, ADMIR - Company’s t wo lead ...
- Inaugural a ppointments include globally renowned leaders and experts on attention-deficit/hyperactivity disorder (ADHD) and stimulant abuse PHILADELPHIA, PA, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON)...
Shares of Vallon Pharmaceuticals Inc. (NASDAQ:VLON) traded today at $10.20, eclipsing its 52-week high. This new high was reached on above average trading volume as 535,000 shares traded hands, while the average 30-day volume is approximately 309,000 shares. Vallon Pharmaceuticals Inc. (...
Gainers: Regional Health Properties (NYSE:RHE) +55%. AC Immune (NASDAQ:ACIU) +34%. Net Element (NASDAQ:NETE) +27%. Vallon Pharmaceuticals (NASDAQ:VLON) +25%. Spok (NASDAQ:SPOK) +23%. Elys Game Technology (NASDAQ:ELYS) +21%. Youdao (NYSE:DAO) +20%. Qualigen Therapeutics (NASDAQ:QLGN) +18%. Azu...
Live video webcast with David Baker, President and CEO of Vallon , on Wednesday , August 18 th 12 : 30 PM ET PHILADELPHIA, PA, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (...
- Company continues to drive enrollment in pivotal intranasal abuse study evaluating ADAIR toward completion before year-end 2021 - ADAIR targeting the large and growing Adderall ® segment of the ~$9 billion US ADHD market PHILADE...
Vallon Pharmaceuticals ([[VLON]] -6.1%) announces that the European Patent Office has issued patent number EP3576719B1 covering ADAIR, the Company’s proprietary abuse-deterrent formulation of immediate-release dextroamphetamine.The new European patent covers composition of matter and m...
- Patent bolsters intellectual property protection as Company’s partner, MEDICE, works to develop and potentially commercialize ADAIR in Europe and the UK PHILADELPHIA, PA, July 13, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON), (“Vallon...
Vallon Pharmaceuticals (VLON): Q1 net loss of $2.6MCash and cash equivalents of ~$13.0M, which the Company expects will provide funding for its ongoing business activities into the third quarter of 2022.Shares are up 2.67% PM.Press Release For further details see: Vallon Pharm...
News, Short Squeeze, Breakout and More Instantly...
Vallon Pharmaceuticals Inc. Company Name:
VLON Stock Symbol:
NASDAQ Market:
Combined company will operate as GRI Bio , Inc. and advance i nnovative p ipeline of Natural Killer T ( “ NKT ” ) modulating therapies for the treatment of i nflammatory, f ibrotic and a utoimmune d ...
Vallon’s b oard approves 1-for-30 r everse stock split Merger expected to close April 21, 2023 PHILADELPHIA, PA, April 20, 2023 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) (“Vallon” or the “Company”) toda...
Board of Directors unanimously recommend Vallon stockholders to vote “ FOR ” all proposals outlined in the Company’s definitive Proxy Statement (the “Proxy”) in order to close the proposed merger with GRI Bio , Inc. ...